-
The untold Side of the movie "Dallas Buyers Club"
The movie Dallas Buyers Club brings attention to a little-recognized part of the AIDS activist movement: ....
-
Exhorbitant Price New Hepatitis C Drug
Fair Pricing Coalition Condemns Gilead Sciences on the High Price of New Hepatitis C Drug Sovaldi™...
-
Six Promising HIV Drugs in the Pipeline (2013-2014)
What new HIV medications do we have to look forward to over the next few years? How will these newer drugs improve upon the older ones? To shed some light on these questions....
-
What Can We Look Forward to in HIV Cure Research
TheBodyPRO.com's Nelson Vergel sat down with leading HIV cure research activist Richard Jefferys for an update on current important aspects, and controversies, in HIV cure research....
-
What Supplements Can I take with HIV medications?
Is it ok to supplement with Creatine (Cell-Tech), and Protein (Nitro-Tech) along with Glutamine...
Friday, June 06, 2014
HIV-Positive Venezuelans Are Desperately Seeking HIV Medications- Please Help
Thursday, June 05, 2014
AIDS SURVIVORS SUMMIT SAN FRANCISCO CONVENED ON JUNE 5, 2014 NATIONAL HIV/AIDS LONG-TERM SURVIVORS AWARENESS DAY
Bill sponsored by HIV-Positive Legislator Advances Tuesday to Help People with HIV-related Lipodystrophy
Statin Therapy Does Not Improve Cardiovascular Risk for Patients With HIV and Low HDL
The main lipid abnormality of people living with HIV is low high density lipoprotein (HDL). There are 5 subfractions of HDL: 2a, 2b, 3a, 3b, and 3c, from largest (and most effective in cholesterol removal) to smallest (and least effective).
Neither pravastatin nor rosuvastatin changes the distribution of high-density lipoprotein (HDL) subfractions in patients who are HIV-seropositive with severe dyslipidaemia undergoing treatment with a combined antiretroviral therapy (cART) and protease inhibitor, according to substudy results presented at the 82nd European Atherosclerosis Society (EAS) Congress.
- Get aerobic exercise. Moderate to vigorous aerobic exercise can boost HDL by 5% to 10%. Aim for five 30-minute sessions per week.
- Lose weight if you need to. If you’re overweight or obese, you can boost your HDL level by about 1 mg/dL for every seven pounds lost, although any amount of weight loss will help.
- If you smoke, quit. HDL levels rise by as much as 15% to 20% after you quit.
- Eat a healthy diet. Avoid trans fats, which increase bad cholesterol and decrease good cholesterol. Avoid highly refined carbohydrates, such as white-flour products.
- Consider medications. Niacin, available over the counter, is the most effective HDL-raising medication available. Niacin can be strong medicine — work with your clinician if you want to try it. NAC is also a good supplement to consider.
- Avoid higher doses of testosterone
Wednesday, May 28, 2014
New CDC Guidelines: People at Risk for HIV Should Consider Truvada PrEP
Saturday, May 24, 2014
PMMA-microspheres for the treatment of HIV-associated buttock lipodystrophy.
Soft tissue augmentation with PMMA-microspheres for the treatment of HIV-associated buttock lipodystrophy.
Authors
Serra MS, et al.Journal
Affiliation
Abstract
Tuesday, January 21, 2014
The untold side of the movie "Dallas Buyers Club"
The movie Dallas Buyers Club brings attention to a little-recognized part of the AIDS activist movement: the desperate struggle to provide anything that might treat the disease when no treatment was available.
AL-721, Compound Q, Peptide T—buyers clubs formed around the country to bring in potential treatments, whether pharmaceutical or botanical, for both the virus and its effects. Many of these treatments, if not most, were not approved by the Food and Drug Administration (FDA) or not approved for the use for which they were taken.
Vitamins and other nutritional supplements were also sold, in many instances (if not most) at deeply discounted prices.
As shown by the smuggling in the movie, there were illegal risks taken, all in the name of saving lives. Also as shown in the movie, people with AIDS risked their lives on unproven therapies, all in the hope of surviving a disease at a time when it was killing people in large numbers.
“We wanted to live, but we were also desperate,” said longtime AIDS activist and writer Matt Sharp.
More here
Monday, December 09, 2013
Activists Condemn Gilead for Exhorbitant Price of Their New Hepatitis C Drug

For Immediate Release December 9, 2013
Contact: Lynda Dee 410-332-1170 or lyndamdee@aol.com
Fair Pricing Coalition Condemns Gilead Sciences on the High Price of New Hepatitis C Drug Sovaldi™, and Urges Rapid and Wide Dissemination of Support Program Details for Uninsured and Underinsured People Living with Hepatitis C
The Fair Pricing Coalition (FPC) today condemned Gilead Sciences for the price set for its direct acting antiviral (DAA) Sovaldi™ (sofosbuvir), a once-daily, first- in-class nucleotide polymerase inhibitor approved by the U.S. Food and Drug Administration on December 6, 2013, for the treatment of chronic hepatitis C,including those co-infected with HIV. While FPC believes that all hepatitis C virus (HCV) drugs are priced too high, the coalition of HIV and viral hepatitis treatment activists is especially dismayed by the wholesale acquisition cost (WAC) of $84,000 for a 12-week course of Sovaldi™. For comparison purposes, the FPC notes the 12-week WAC for the recently approved NS3/4A protease inhibitor Olysio™ (simeprevir) is $66,360.
“Sovaldi™ is a very safe and highly effective drug that will significantly shorten HCV therapy and either reduce or eliminate the need for injected pegylated interferon,” explained FPC Co-Chair Lynda Dee. “However, this does not give Gilead unconscionable pricing carte blanche, particularly when considering that Sovaldi™ still needs to be combined with ribavirin for the treatment of HCV genotype 2 for 12 weeks or genotype 3 for 24 weeks.
Wednesday, October 09, 2013
Briefing at Congress: The Changing Face of HIV/AIDS in America
Saturday, October 05, 2013
Once a Month HIV Medications - Cost Effectiveness
Long-acting antiretroviral (ARV) formulations, now in clinical development, could prolong survival in people with HIV, according to results of a modeling study [1]. But the benefit may hold true only in people with barriers to good adherence. Although long-acting antiretrovirals may not be cheap, the researchers determined they could be "a good value" when used mainly for poorly adherent patients.










